BEVACIZUMAB AS THERAPY FOR RADIATION NECROSIS IN FOUR CHILDREN WITH PONTINE GLIOMAS

ARTHUR K. LIU, M.D., PH.D.,* MARGARET E. MACY, M.D., † AND NICHOLAS K. FOREMAN, M.R.C.P. †

*University of Colorado Denver, Department of Radiation Oncology, Aurora, CO; †The Children’s Hospital, Denver, Department of Neuro-Oncology, Aurora, CO

Purpose: Diffuse pontine gliomas are a pediatric brain tumor that is fatal in nearly all patients. Given the poor prognosis for patients with this tumor, their quality of life is very important. Radiation therapy provides some palliation, but can result in radiation necrosis and associated neurologic decline. The typical treatment for this necrosis is steroid therapy. Although the steroids are effective, they have numerous side effects that can often significantly compromise quality of life. Bevacizumab, an antibody against vascular endothelial growth factor, has been suggested as a treatment for radiation necrosis. We report on our initial experience with bevacizumab therapy for radiation necrosis in pediatric pontine gliomas.

Materials and Methods: Four children with pontine gliomas treated at the Children’s Hospital in Denver and the University of Colorado Denver developed evidence of radiation necrosis both clinically and on imaging. Those 4 children then received bevacizumab as a treatment for the radiation necrosis. We reviewed the clinical outcome and imaging findings.

Results: After bevacizumab therapy, 3 children had significant clinical improvement and were able to discontinue steroid use. One child continued to decline, and, in retrospect, had disease progression, not radiation necrosis. In all cases, bevacizumab was well tolerated.

Conclusions: In children with pontine gliomas, bevacizumab may provide both therapeutic benefit and diagnostic information. More formal evaluation of bevacizumab in these children is needed.
worsening from presumed radiation necrosis. Three of the 4 received radiation therapy consisting of stereotactic radiotherapy to the tumor to a dose of 54 Gy in 1.8 Gy fractions. One child received a short course of radiation therapy, 25 Gy in 5-Gy fractions, to allow the child to return home more quickly. Two children received an investigational agent on a Phase I trial along with standard radiation therapy as initial therapy. The 4 children are described in detail.

Patient 1 presented with a 2-week history of ataxia and speech difficulty. Magnetic resonance imaging (MRI) revealed a pontine mass with areas concerning for necrosis. She received conventional radiation therapy (54 Gy in 1.8-Gy fractions). Within 3 weeks of starting therapy, her neurologic function had returned to baseline. MRI performed at the end of radiation showed a decrease in the size of the pontine mass with necrosis on the right. Three months after completion of radiation, she developed significant left-sided weakness, slurred speech, and facial droop. The MRI revealed an increase in the right-sided area of necrosis (Fig. 1, row A). She responded to Decadron treatment and was then started on bevacizumab therapy with significant improvement in weakness. She received a total of five courses of bevacizumab. Repeat imaging 2 months later showed decreased enhancement in the region of necrosis (Fig. 1, row B). She has subsequently progressed, both clinically and radiographically. She was briefly enrolled on a Phase I trial, but continued to have progressive symptoms and was placed on terminal care. She is alive with disease 10 months from initial diagnosis.

Patient 2 presented with a 3-week history of ataxia, slurred speech, right-sided weakness, and fatigue. MRI revealed an infiltrating pontine mass with a region of necrosis on the left. He received conventional radiation therapy and a concurrent Phase I agent. Before starting radiation treatment, he developed a tachycardic/bradycardic rhythm, somnolence, and

Fig. 1. Two consecutive axial slices from the post-gadolinium T1-weighted magnetic resonance imaging performed 3 months after completion of therapy (row A) and after 2 months of bevacizumab therapy (row B).
worsening neurologic functioning. His radiation treatments were started urgently and he responded to mannitol and Decadron. Within 1 week of starting radiation, he had improvement in his level of consciousness and neurologic function. By the end of radiation, he had minimal cranial nerve palsies but moderate residual right weakness.

Fig. 2. Three consecutive axial slices from the post-gadolinium T1-weighted and fluid attenuated inversion recovery magnetic resonance imaging performed 3 weeks after completion of therapy (rows A, C) and after 1 month of bevacizumab therapy (rows B, D).
Three weeks after completion of treatment, he developed ataxia, right-sided weakness, and significant nausea and vomiting. MRI at that time revealed a decrease in the size of the tumor with marked cystic radiation necrosis on the left (Fig. 2, rows A and C). He was started on Decadron and subsequently bevacizumab. His gait and weakness rapidly improved. Follow-up imaging 3 weeks later revealed significant improvement, with a decrease in enhancing necrotic region and edema seen on the fluid attenuated inversion recovery sequence (Fig. 2, rows B and D). He has received five courses of bevacizumab and did well clinically for 4 months. He now has progressed clinically and on imaging and is alive with disease 7 months from initial diagnosis.

Patient 3 presented with ataxia, right facial weakness, and left arm and left leg weakness. MRI revealed a pontine mass.
without evidence of necrosis. Initially, his gait and weakness improved with radiation treatments. However, during the last week of radiation, he deteriorated with recurrence of his neurologic deficits and MRI revealed a decreased tumor with new development of radiation necrosis on the right. He initially responded to Decadron, but then 1 month later began to deteriorate again as he tapered off the steroids. The MRI performed demonstrated progression of the necrosis (Fig. 3, rows A and C). He then received four courses of bevacizumab with good improvement, both clinically and by imaging.

Fig. 4. Three consecutive axial slices from the post-gadolinium T1-weighted magnetic resonance imaging at initial presentation (row A), 3 months after completion of therapy (row B), and after three courses of bevacizumab (row C).
(Fig. 3, rows B and D). He is doing well 5 months from initial diagnosis.

Patient 4 presented with ataxia, slurred speech, and left facial weakness. MRI revealed a right-sided pontine lesion (Fig. 4, row A). Given the atypical appearance of the mass, he underwent stereotactic biopsy; pathology revealed glioblastoma. After extensive discussions with the parents, they chose to undergo a short course of palliative radiation therapy to allow him to return home more quickly. He received 25 Gy in five fractions. He responded very well and within a few weeks had returned to baseline functioning. Three months after completion of radiation, he developed left-sided weakness, MRI showed increased enhancement in the tumor and increasing edema, consistent with radiation necrosis (Fig. 4, row B). He was started on Decadron and improved dramatically over the next few weeks. However, as the steroid was tapered, his weakness returned. He received three courses of bevacizumab while attempting to decrease his Decadron. However, his weakness progressively worsened and MRI revealed progressive disease (Fig. 4, row C). He died 6 months after initial diagnosis.

**DISCUSSION**

Necrosis occurs frequently in children with DPGs that receive radiation therapy. In one series, 28 of 29 children developed necrosis after treatment (7). The necrosis likely results from a combination of radiation therapy and the biology of the tumor itself. Early tumor necrosis resulting in symptoms is more likely to be treatment-related and can improve over time in many cases (8). The treatment for radiation necrosis is typically steroids, which nonspecifically reduces edema, but is associated with numerous significant side effects.

Endothelial abnormalities, including elevation in vascular endothelial growth factor, play a significant role in the development of radiation necrosis (9–12). Agents that interfere with the vascular endothelial growth factor signaling pathways have been shown to reduce vascular permeability and decrease edema in glioblastoma patients (13). It seems reasonable to hypothesize that vascular normalization would similarly improve radiation necrosis. This has been shown in a small group of 8 adults with brain tumors treated at M.D. Anderson Cancer Center who received bevacizumab for radiation necrosis. Reductions in contrast enhancement and fluid attenuated inversion recovery MRI abnormalities were seen on imaging and correlated with reductions in steroid requirements (5). Similarly, at Beth Israel Deaconess Medical Center in Boston, 1 patient with temporal lobe necrosis after treatment for nasopharyngeal carcinoma was treated with bevacizumab (6). She had reduction of enhancement on MRI along with neurocognitive improvement.

There is less experience with bevacizumab in the pediatric population, but it appears to be very well tolerated in early clinical trials (14, 15). These two trials treated a total of 36 children with refractory or recurrent solid tumors, including brain tumors. Side effects included hematologic toxicity, abnormal liver function tests, hypertension, epistaxis, nausea, weight loss, mucositis, cough, hematuria, proteinuria, poor wound healing, erythema, and rash. There were no Grade III or higher toxicities seen.

We similarly found bevacizumab was very well tolerated. Our patients reported no additional toxicity related to bevacizumab. Three of the 4 children were able to discontinue steroids and had significant clinical improvement in neurologic symptoms caused by radiation necrosis. The fourth child did not respond to bevacizumab and was unable to wean off steroids, but in retrospect appeared to have progressive disease.

It is difficult to distinguish between treatment-related necrosis and disease progression with conventional imaging (16, 17). Our experience suggests that bevacizumab can be both therapeutic and diagnostic for radiation necrosis. Children who do not respond to bevacizumab therapy may have progressive disease rather than radiation necrosis. Even in patients with such a poor prognosis, this distinction is important for the family and allows consideration of additional therapy or enrollment in Phase I trials.

With this very small number of children, it is not possible to make definitive treatment recommendations. However, the results are promising and suggest that bevacizumab provides symptom relief from radiation necrosis with minimal toxicity. For children with diffuse pontine gliomas, treatment is essentially palliative and quality of life is of paramount concern. Based on this initial cohort of children treated, we are planning on a more formal trial to study the safety and efficacy of bevacizumab in these children.

**REFERENCES**


